<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref107">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>O’brien</surname>
    <given-names>K. L.</given-names>
   </name>
   <name>
    <surname>Chandran</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Weatherholtz</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Jafri</surname>
    <given-names>H. S.</given-names>
   </name>
   <name>
    <surname>Griffin</surname>
    <given-names>M. P.</given-names>
   </name>
   <name>
    <surname>Bellamy</surname>
    <given-names>T.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2015</year>). 
  <article-title>Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy native American infants: a phase 3 randomised double-blind placebo-controlled trial</article-title>. 
  <source>Lancet Infect. Dis.</source>
  <volume>15</volume>, 
  <fpage>1398</fpage>–
  <lpage>1408</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S1473-3099(15)00247-9</pub-id>, PMID: 
  <?supplied-pmid 26511956?>
  <pub-id pub-id-type="pmid">26511956</pub-id>
 </mixed-citation>
</ref>
